儿童慢性肾脏病患者导航员项目的试验内经济学评价
NAVKIDS2试验在澳大利亚儿童慢性肾脏病患者中比较患者导航与标准照护。6个月人均总费用导航组10249澳元高于标准组9368澳元(P<0.001),但平均医疗费用无显著差异(9848 vs 9368澳元,P=0.98),导航员额外费用1075澳元/人。6个月总QALY无显著差异(0.33 vs 0.30,P=0.11),ICER为41960澳元/QALY,95%CI宽(-300123至769958),不确定性大。
要点
- 导航组6个月人均总费用10249澳元高于标准组9368澳元,差异有统计学意义(P<0.001)。
- 平均医疗费用两组无显著差异(导航组9848 vs 标准组9368澳元,P=0.98),导航员额外费用1075澳元/人。
- 6个月QALY两组无显著差异(导航组0.33 vs 标准组0.30,P=0.11),ICER为41960澳元/QALY,95%CI宽。
核心结论
- 经济学评价发现患者导航员费用相对于总医疗费用较低,但干预的成本效果存在相当大的不确定性。
- 需要进一步研究评估长期成本效果以及对健康结局和医疗资源利用的潜在影响。
研究设计与样本
- NAVKIDS2试验的试验内经济学评价,比较患者导航与标准照护。
- 从医疗保健供方视角前瞻性收集6个月的费用和资源利用数据,费用以澳元报告。
- 生活质量数据收集时间为0至6个月,增量成本效果比以额外成本/获得的质量调整生命年报告。
主要发现
- 6个月人均总费用导航组10249澳元 vs 标准组9368澳元,P<0.001。
- 平均医疗费用导航组9848澳元 vs 标准组9368澳元,P=0.98,无显著差异;导航组因患者导航员产生额外费用1075澳元/人。
- 6个月总QALY导航组0.33 vs 标准组0.30,P=0.11,无显著差异。
- 与常规照护相比,干预组ICER为41960澳元/QALY,95%CI为-300123至769958澳元,提示相当大的不确定性。
关键数值与推荐
- 费用以澳元报告。
- 增量成本效果比以额外成本/获得的质量调整生命年报告。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出成本效果存在相当大的不确定性(ICER 95%CI宽:-300123至769958澳元)。
- 原文指出需要进一步研究评估长期成本效果以及对健康结局和医疗资源利用的潜在影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The NAVKIDS2 trial was a patient navigation program for children and their caregivers living with chronic kidney disease (CKD) in Australia. We conducted a within-trial economic evaluation to describe the cost-effectiveness of patient navigation compared with standard care. METHODS: Cost and resource utilization data were prospectively collected over 6 months, from a health care funder perspective. Costs were reported in Australian dollars. Quality-of-life (QoL) data were collected from 0 to 6 months. Incremental cost-effectiveness ratios (ICERs) were reported as the additional cost/quality-adjusted life years (QALYs) gained. RESULTS: Over the 6-month period, total per-patient costs were higher in the patient navigation group than in those in the standard care group ($10,249 vs. $9368, respectively; P < 0.001). There was no significant difference in mean health care costs between the 2 groups ($9848 vs. $9368, respectively, P = 0.98); however, the intervention group incurred an additional cost of $1075/person for the patient navigator. There was no significant difference in total QALYs over 6 months between patient navigation and standard care groups (0.33 vs. 0.30, respectively; P = 0.11). The ICER for the intervention group compared with usual care was $41,960/QALY gained with a wide 95% confidence interval (CI) (-$300,123 to +$769,958), indicating substantial uncertainty. CONCLUSION: The economic evaluation found that the cost of patient navigators is relatively low compared with total health care costs; however, there is considerable uncertainty regarding the cost-effectiveness of the intervention. Further research is needed to evaluate long-term cost-effectiveness as well as potential impacts on health outcomes and health care utilization.
引用
- Chen W, Wong G, Howard K, et al. A Within-Trial Economic Evaluation of a Patient Navigator Program in Children With CKD. Kidney Int Rep. 2025. PMID: 40980675. doi:10.1016/j.ekir.2025.06.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。